MESO logo

MESO Mesoblast Limited

NASDAQ Global Select · Biotechnology · Healthcare

$10.89
-0.29 (-2.59%)

Mesoblast Limited, an Australian enterprise established in Melbourne in 2004, is dedicated to developing innovative regenerative medicine products. The company's global reach extends to the United States, Singapore, the United Kingdom, and Switzerland. Its therapeutic endeavors encompass a wide array of medical conditions, including cardiovascular diseases, spinal and orthopedic ailments, oncology…

Market Cap: $1.41Bwww.mesoblast.com

Price

No data yet.

Social Signal Score

49
5d
50
2 mentions
—
30d
50
6 mentions
—
60d
45
8 mentions
—
90d
50
11 mentions
—
news: 11

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 5Hold 4Sell 2Strong Sell 0
Avg price target$39+258.1%
Low $39Median $39High $39
Current Consensus

Revenue

$34.45M+8622.53%
$395.0K$11.75M$23.10M$34.45M
Sep 2016Jun 2026

Analyst Estimates

FY2026
$-0.44
$-0.51–$-0.37
2 analysts
FY2027
$-0.20
$-0.28–$-0.11
2 analysts
FY2028
$0.23
$0.19–$0.25
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Silviu Itescu
Sector
Healthcare
Industry
Biotechnology
Employees
108
Beta
0.81
Country
AU
Piotroski score
3 / 9 (Weak)
Altman Z-score
2.33
www.mesoblast.com